替吉奥联合奈达铂作为Ⅱ~Ⅲa期肺鳞状细胞癌术后辅助治疗方案的临床研究(1)
【摘要】 目的：探討替吉奥联合奈达铂作为Ⅱ～Ⅲa期肺鳞状细胞癌术后辅助治疗方案的疗效和安全性。方法：选择2017年3-9月笔者所在医院收治的60例Ⅱ～Ⅲa期肺鳞状细胞癌术后患者为研究对象，将其随机分为试验组和对照组，每组30例。试验组接受替吉奥联合奈达铂辅助治疗。对照组接受吉西他滨联合奈达铂辅助治疗。比较两组2年无复发生存率(RFS)、安全性。结果：试验组2年RFS为46.7%，对照组2年RFS为50.0%，两组比较差异无统计学意义(HR=1.137，95%CI：0.625，2.068，P=0.675)。血液学毒性方面，对照组贫血和血小板减少症发生率分别为36.7%、30.0%，均显著高于试验组的3.3%、6.7%，差异有统计学意义(P<0.05)。非血液学毒性方面，对照组疲劳和恶心呕吐发生率分别为26.7%、33.3%，均明显高于试验组的3.3%，10.0%，差异有统计学意义(P<0.05)。结论：作为Ⅱ～Ⅲa期肺鳞状细胞癌术后辅助治疗方案，替吉奥联合奈达铂疗法不劣效于吉西他滨联合奈达铂疗法，不良反应低，可作为Ⅱ～Ⅲa期肺鳞状细胞癌术后辅助治疗的一种选择。
【关键词】 替吉奥 奈达铂 肺鳞状细胞癌 术后辅助治疗
doi：10.14033/j.cnki.cfmr.2020.16.006 文献标识码 B 文章编号 1674-6805(2020)16-00-04
The Clinical Research on Tegafur， Gimeracil and Oteracil Potassium Combined with Nedaplatin as Postoperative Adjuvant Therapy for Stage Ⅱ to Ⅲa Squamous Cell Carcinoma of the Lung/LIN Heng， ZANG Huanping， ZHU Jinxiu. //Chinese and Foreign Medical Research， 2020， 18(16)： -19
[Abstract] Objective： To investigate the clinical effect and safety of Tegafur， Gimeracil and Oteracil Potassium combined with Nedaplatin as postoperative adjuvant therapy for stage Ⅱ to Ⅲa squamous cell carcinoma of the lung. Method： Sixty cases for stage Ⅱ to Ⅲa postoperative patients with squamous cell carcinoma of the lung admitted in our hospital from March to September 2017 were selected and randomly divided into the experimental group and the control group， with 30 cases in each group. The experimental group was treated with Tegafur， Gimeracil and Oteracil Potassium combined with Nedaplatin. The control group was treated with Gemcitabine combined with Nedaplatin. Two year recurrence free survival (RFS) and safety were compared between the two groups. Result： The RFS rate at 2 years was 46.7% in the experimental group and 50.0% in the control group. There was no significant difference between two group (HR=1.137， 95%CI： 0.625， 2.068， P=0.675). In terms of hematological toxicity， the incidence rates of anemia and thrombocytopenia in the control group were 36.7% and 30.0%， respectively， which were both significantly higher than 3.3% and 6.7% in the experimental group， and the differences were statistically significant (P<0.05). In terms of non-hematological toxicity， the incidence of fatigue， nausea and vomiting in the control group was 26.7% and 33.3%， respectively， which were significantly higher than 3.3% and 10.0% in the experimental group， and the differences were statistically significant (P<0.05). Conclusion： As an adjuvant therapy for stage Ⅱ to Ⅲa squamous cell carcinoma of the lung， Tegafur， Gimeracil and Oteracil Potassium combined with Nedaplatin is not inferior to Gemcitabine combined with Nedaplatin， with low side effects， which can be used as an alternative for adjuvant therapy for stage Ⅱ to Ⅲa squamous cell carcinoma of the lung., 百拇医药(林恒 臧焕平 朱金秀)
【关键词】 替吉奥 奈达铂 肺鳞状细胞癌 术后辅助治疗
doi：10.14033/j.cnki.cfmr.2020.16.006 文献标识码 B 文章编号 1674-6805(2020)16-00-04
The Clinical Research on Tegafur， Gimeracil and Oteracil Potassium Combined with Nedaplatin as Postoperative Adjuvant Therapy for Stage Ⅱ to Ⅲa Squamous Cell Carcinoma of the Lung/LIN Heng， ZANG Huanping， ZHU Jinxiu. //Chinese and Foreign Medical Research， 2020， 18(16)： -19
[Abstract] Objective： To investigate the clinical effect and safety of Tegafur， Gimeracil and Oteracil Potassium combined with Nedaplatin as postoperative adjuvant therapy for stage Ⅱ to Ⅲa squamous cell carcinoma of the lung. Method： Sixty cases for stage Ⅱ to Ⅲa postoperative patients with squamous cell carcinoma of the lung admitted in our hospital from March to September 2017 were selected and randomly divided into the experimental group and the control group， with 30 cases in each group. The experimental group was treated with Tegafur， Gimeracil and Oteracil Potassium combined with Nedaplatin. The control group was treated with Gemcitabine combined with Nedaplatin. Two year recurrence free survival (RFS) and safety were compared between the two groups. Result： The RFS rate at 2 years was 46.7% in the experimental group and 50.0% in the control group. There was no significant difference between two group (HR=1.137， 95%CI： 0.625， 2.068， P=0.675). In terms of hematological toxicity， the incidence rates of anemia and thrombocytopenia in the control group were 36.7% and 30.0%， respectively， which were both significantly higher than 3.3% and 6.7% in the experimental group， and the differences were statistically significant (P<0.05). In terms of non-hematological toxicity， the incidence of fatigue， nausea and vomiting in the control group was 26.7% and 33.3%， respectively， which were significantly higher than 3.3% and 10.0% in the experimental group， and the differences were statistically significant (P<0.05). Conclusion： As an adjuvant therapy for stage Ⅱ to Ⅲa squamous cell carcinoma of the lung， Tegafur， Gimeracil and Oteracil Potassium combined with Nedaplatin is not inferior to Gemcitabine combined with Nedaplatin， with low side effects， which can be used as an alternative for adjuvant therapy for stage Ⅱ to Ⅲa squamous cell carcinoma of the lung., 百拇医药(林恒 臧焕平 朱金秀)